A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Trial details
- Registry ID
- NCT05980806
- Phase
- Phase 2
The FDA approved Momelotinib (OJJAARA) on 15 Sep 2023.
Drug identity checked against registry records
Also recorded as OJJAARA
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaNCT05980806 | KPTI | Phase 2 | Recruiting | 2027-06Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2023-09-15Day | Momelotinib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA216873", "applicant_as_listed_by_fda": "GLAXOSMITHKLINE", "brand_names": ["OJJAARA"], "active_ingredients": ["MOMELOTINIB DIHYDROCHLORIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20230915", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |